Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment

Gastroenterology. 2011 Nov;141(5):1673-9. doi: 10.1053/j.gastro.2011.06.053. Epub 2011 Jun 30.

Abstract

Background & aims: We documented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the association between large shunts and response to treatment.

Methods: We performed a retrospective case-control study of data from patients with mild (mean pulmonary artery pressure [MPAP], 25-35 mm Hg; n = 18), moderate (MPAP, 35-50 mm Hg; n = 45), and severe POPH (MPAP, >50 mm Hg; n = 16). Data were compared with those from controls (normal echocardiography with estimated right ventricular systolic pressure, <35 mm Hg; n = 122). Spontaneous portosystemic shunts greater than 10 mm in diameter, identified by computed tomography or magnetic resonance, were classified as large. Response to treatment at 6 months was defined by right ventricular systolic pressure or MPAP as significant (<35 mm Hg), partial (35-50 mm Hg), or no response (>50 mm Hg).

Results: The frequency of spontaneous shunts did not differ significantly between groups of subjects with severe (n = 14 of 16), moderate (n = 38 of 45), or mild POPH (n = 11 of 18) or normal echocardiograms (controls, n = 86 of 122) (P = .77). Large shunts were associated with severe (14 of 16) and moderate POPH (32 of 45), compared with mild POPH (6 of 18) or controls (30 of 122) (P < .01). In 13 patients with severe POPH, large shunts were associated with lack of response to treatment in 90% (8 of 9) or partial response in 50% (2 of 4). Among 27 patients with moderate POPH, large shunts were associated with no response to treatment in 13 of 19 (68%) and a partial response in 2 of 6 (33%).

Conclusions: Large spontaneous portosystemic shunts are associated significantly with moderate and severe POPH, and with lack of response to treatment.

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Bosentan
  • Case-Control Studies
  • Child
  • Drug Therapy, Combination
  • Epoprostenol / therapeutic use
  • Female
  • Humans
  • Hypertension, Portal / drug therapy*
  • Hypertension, Portal / physiopathology*
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / physiopathology*
  • Magnetic Resonance Imaging
  • Male
  • Mesentery / diagnostic imaging
  • Mesentery / pathology
  • Mesentery / physiopathology*
  • Middle Aged
  • Piperazines / therapeutic use
  • Purines / therapeutic use
  • Regional Blood Flow / physiology
  • Renal Veins / diagnostic imaging
  • Renal Veins / pathology
  • Renal Veins / physiopathology*
  • Retrospective Studies
  • Severity of Illness Index
  • Sildenafil Citrate
  • Splenic Vein / diagnostic imaging
  • Splenic Vein / pathology
  • Splenic Vein / physiopathology*
  • Sulfonamides / therapeutic use
  • Sulfones / therapeutic use
  • Tomography, Spiral Computed
  • Treatment Outcome
  • Vena Cava, Inferior / diagnostic imaging
  • Vena Cava, Inferior / pathology
  • Vena Cava, Inferior / physiopathology*

Substances

  • Antihypertensive Agents
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Sildenafil Citrate
  • Epoprostenol
  • Bosentan